# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Nikola Tesla (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI009-SYN
- Date: 2026-06-30
- Fictional facility: St. Posthumous Health Center
- Fictional author: Branimir Kovač-Holt, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Twenty-four-week OCD treatment review. **S**

## History of present illness

Mr. Tesla returns twelve weeks after the increase to sertraline 150 mg. At the nurse telephone check two weeks after the increase he reported mild sweating and no other side effects. He now has mild delayed ejaculation, which he finds acceptable, and has missed no doses. The Y-BOCS his therapist was to rate at about week eighteen was not done: that session was spent on an exposure at his laboratory and no rating was rescheduled. He has had eighteen ERP sessions and will finish the course next month. His rituals take about 45 minutes a day; he still counts steps on some walks but can stop. He eats three meals a day without calculating, sleeps about six hours, and has stopped working after midnight. He has had no suicidal thoughts. **S**

| Element | Detail |
|---|---|
| Missed rating | Therapist's Y-BOCS at about week eighteen not done |
| Sertraline | Mild sweating and delayed ejaculation; no missed doses |
| Rituals | About 45 minutes a day |
| Nutrition and sleep | Three meals a day; about six hours of sleep |
| Safety | No suicidal thoughts |
| Y-BOCS | 13, down from 28 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight up 3.1 kg since intake; energy good |
| Genitourinary | Positive | Mild delayed ejaculation on sertraline |
| Integumentary | Negative | Hands normal; mild sweating |
| Psychiatric | Negative | Obsessions infrequent and brief; mood good; no suicidal thoughts |

4 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, three tablets (150 mg) by mouth each morning **S**
- White petrolatum ointment, apply to both hands after each wash and at bedtime **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/72 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 66.9 kg; BMI 18.9 kg/m². All vital signs are synthetic.

PHQ-9: 3; GAD-7: 5; Vitamin B12: 412 pg/mL; Albumin: 4.2 g/dL. All results are synthetic.

## Change since baseline

- PHQ-9: 8 at baseline, 3 at this visit **S**
- GAD-7: 12 at baseline, 5 at this visit **S**
- Vitamin B12: 284 pg/mL at baseline, 412 pg/mL at this visit **S**
- Albumin: 3.8 g/dL at baseline, 4.2 g/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Slim, relaxed, and animated |
| Mental status | Articulate and humorous; mood "like a weight lifted"; affect full; good insight; no suicidal ideation |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Obsessive-compulsive disorder, responding** (F42.2). Y-BOCS 13, down 54 percent from 28: a clear response after twelve weeks at 150 mg with ERP. PHQ-9 3 and GAD-7 5. Delayed ejaculation is mild and acceptable to him. Suicide risk remains low. **S**
   - Continue sertraline 150 mg for at least one to two years before any slow taper.
   - Finish the ERP course, then monthly booster sessions; relapse-prevention plan with his therapist.
   - Collaborative safety plan reviewed and unchanged; 988 Suicide & Crisis Lifeline and the clinic number confirmed.
2. **Underweight, resolved** (R63.6). 66.9 kg, BMI 18.9; albumin 4.2 g/dL and vitamin B12 412 pg/mL. **S**
   - Keep three meals a day; weight at each visit.
3. **Insufficient sleep, resolved** (Z72.820). About six hours a night with no work after midnight. **S**
   - Keep the fixed sleep window.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Y-BOCS severity score (recorded in the note; no LOINC code found) | At baseline and about every 4 to 6 weeks during acute treatment | Completed today | 13, down 54 percent from 28: response |
| Survey | Interim Y-BOCS between the twelve-week review and today | At baseline and about every 4 to 6 weeks during acute treatment | Deferred | Not done, a deviation from the protocol: the therapist's Y-BOCS planned at about week eighteen was not done because that session was used for an exposure and no rating was rescheduled, leaving twelve weeks without a severity score during the titration. No harm resulted judging by today's score and review: he responded and had no suicidal thoughts. Corrective action: the therapist now enters a Y-BOCS in the shared record every sixth session, and the clinic registry flags a missing score |
| Survey | PHQ-9 and GAD-7 for secondary depression and anxiety | At baseline and periodically while depressive or anxiety symptoms are present | Completed today | PHQ-9 3 (item 9 scored 0); GAD-7 5 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9 when given) | Every visit during acute treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Protective factors stronger than at intake. Safety plan reviewed |
| Medication safety | Sertraline adherence and adverse effects (nausea, diarrhea, sleep, activation, sexual effects) | Every visit and two weeks after each dose increase | Completed today | Nurse call two weeks after the increase: mild sweating only. Today mild delayed ejaculation, acceptable to him; no missed doses |
| Self-management | Exposure and response prevention attendance and homework | Every visit during acute treatment | Completed today | Eighteen sessions; course ends next month; booster sessions planned |
| Examination | Weight and BMI | Every visit while underweight | Completed today | 66.9 kg, BMI 18.9, up 3.1 kg since intake |
| Laboratory | Albumin and vitamin B12 after dietary change | Once, after about six months of better intake | Completed today | Albumin 4.2 g/dL; vitamin B12 412 pg/mL |
| Self-management | Sleep diary | Every visit during acute treatment | Completed today | About six hours a night |
| Medication safety | Antipsychotic augmentation monitoring (weight, glucose, lipids, movement) | Only if an antipsychotic is added | Not indicated | No augmentation; responding to sertraline and ERP |

## Goal progress

- Y-BOCS down by at least 35 percent (treatment response) by twenty-four weeks. Outcome by 2026-06-30: Y-BOCS 13 at twenty-four weeks, down 54 percent from 28. **S**
- Rituals under one hour a day, with meals eaten without calculating. Outcome by 2026-06-30: Rituals about 45 minutes a day; most meals eaten without calculation. **S**
- BMI at least 18.5 with three meals a day. Outcome by 2026-06-30: Weight 66.9 kg, BMI 18.9. **S**
- Hands healed, with washing under 15 times a day. Outcome by 2026-04-07: Skin healed; washing about 12 times a day by twelve weeks. **S**
- At least six hours of sleep most nights. Outcome by 2026-06-30: About six hours most nights. **S**

## Guideline basis

- Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007), American Psychiatric Association
- Guideline Watch: Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2013), American Psychiatric Association
- Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) (2005), National Institute for Health and Care Excellence
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense

## Follow-up

- Preventive visit in October; OCD review in about three months. **S**
- Next scheduled visit 2026-10-13: periodic adult preventive visit. **S**
